Please login to the form below

Not currently logged in
Email:
Password:

Castleman's disease

This page shows the latest Castleman's disease news and features for those working in and with pharma, biotech and healthcare.

Roche snags pair of FDA breakthrough designations

Roche snags pair of FDA breakthrough designations

drug. In J-ALEX - conducted by Roche's Japanese subsidiary Chugai - Alecensa reduced the risk of disease-worsening or death by 66% compared to Xalkori. ... First launched in Japan for 2005 for Castleman's disease - and subsequently getting the green

Latest news

  • Roche wins early use RA approval for RoActemra in Europe Roche wins early use RA approval for RoActemra in Europe

    Roche wins early use RA approval for RoActemra in Europe. Adds to existing indications in arthritis and Castleman’ s disease. ... The study showed patients on the combination experienced a significantly greater improvement in disease activity (DAS28

  • EC approves Janssen rare blood disorder drug EC approves Janssen rare blood disorder drug

    EC approves Janssen rare blood disorder drug. Sylvant available to treat multicentric Castleman's disease. ... Janssen's Sylvant this week became the first drug approved in Europe to treat the rare blood disorder multicentric Castleman's disease (MCD).

  • FDA approves Janssen drug for rare Castleman’s disease FDA approves Janssen drug for rare Castlemans disease

    FDA approves Janssen drug for rare Castleman’ s disease. Sylvant approved to treat lymphoma-like condition. ... It is also designated an orphan drug due to the rarity of multicentric Castleman's disease.

  • EMA backs Janssen rare disease drug for approval EMA backs Janssen rare disease drug for approval

    EMA backs Janssen rare disease drug for approval. Castleman's disease treatment Sylvant wins CHMP recommendation. ... J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe.

  • J&J positive about pipeline

    The stable of products that are nearing readiness to be filed with regulators in the US and EU includes bapineuzumab IV for Alzheimer's disease, which the company acquired from Elan ... Also on the list are fulranumab for osteoarthritis pain; siltuximab

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics